Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Primary Immune Thrombocytopenia (ITP)
NCT05885555Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of ianalumab in primary immune thrombocytopenia (ITP), sponsored by Novartis. Primary endpoint: Confirmed response. Started Aug 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05885555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885555.